Sermorelin in 2026: a withdrawn pediatric drug, not a new anti-aging result
Sermorelin is a GHRH(1–29) analog with older diagnostic and pediatric history. Recent marketing is not recent evidence.
Sermorelin is a 29-residue analog of growth-hormone-releasing hormone. It was previously marketed in the U.S. for evaluating and treating some children with growth-hormone deficiency. That branded product was later discontinued; sermorelin is not an approved adult anti-aging drug.
What older human studies showed
They showed that sermorelin can raise GH in people who still have a working pituitary. That is pharmacology. It is not a 2025–2026 demonstration of fat loss, sleep quality, or “safer HGH” in healthy adults.
What did not happen this year
No new landmark RCT redefined sermorelin as a longevity therapy. Compounded sermorelin advertised for wellness sits outside the original labeled use.
Bottom line
Evidence ladder: Human pilot for modern adult wellness claims; older pediatric/diagnostic use is a different question. A pulse of GH is not the same as a proven health outcome.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.